Previous 10 | Next 10 |
home / stock / sdmhf / sdmhf news
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...
Sartorius AG and Sartorius Stedim are a buy after a significant drawdown. Sartorius is operating in the fast-growing biopharmaceutical industry. The company is growing rapidly and with already high profitability. Sartorius French subsidiary is the more attractive stock between...
First-quarter results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 27.6 percent in constant currencies, underlying EBITDA margin 35.2 percent Healthy demand situation; normalization of pandemic-related effects and development of order int...
Sartorius records dynamic start to the new fiscal year PR Newswire Figures for the first quarter of 2022: Sales revenue up 25.4 percent in constant currencies, underlying EBITDA up 32.4 percent, underlying EBITDA margin 34.1 percent Healthy demand situation; normal...
Sartorius Stedim Biotech presents annual report for 2021 PR Newswire AUBAGNE, France , Feb. 17, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the biopharma industry, today has presented its Universal Registration Document 2021 including th...
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 1.26 euros per share to Annual Shareholders' Meeting PR Newswire AUBAGNE, France , Feb. 9, 2022 /PRNewswire/ -- The Board of Directors of Sartorius Stedim Biotech S.A. resolved at toda...
Sartorius Stedim Biotech completes acquisition of Novasep's chromatography division PR Newswire - Sales revenue forecast for 2022 updated due to acquisition AUBAGNE, France , Feb. 8, 2022 /PRNewswire/ -- Sartorius Stedim Biotech, a leading partner of the ...
Preliminary results 2021 of Sartorius Stedim Biotech - Sales revenue up 52.6 percent to 2,887 million euros; underlying EBITDA margin at 35.8 percent, up from 31.7 percent a year ago - Dynamic and profitable organic growth; pandemic-related demand as well as excellent develo...
Nine-month results of Sartorius Stedim Biotech - Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent - Dynamic and profitable organic growth; significant demand momentum generated by the production of coronavirus vaccines as well as st...
Founded in 1870, Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. The company is a leading international backend partner for the biopharmaceutical industry and laboratories. Sartorius Stedim is partnering with McMaster University for advanced research in biomanufactu...
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech Company Name:
SDMHF Stock Symbol:
OTCMKTS Market:
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...